cis-4-[[[1-[(2S)-3-[(2,3-Dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic Acid
UK 79300
Neutral endopeptidase inhibitor. Used in treatment of congestive heart failure.
相关文献及参考
[2]. M Aleksinskaya, et al. Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model. Bmc Pharmacology & Toxicology , 2013 , 14 (1) :1-2.
Kimmelstiel, C.D., et al.: Cardiology, 87, 46 (1996),
Motwani, J.G., et al.: Clin. Pharmacol. Ther., 54, 661 (1993),
[1]. Bevan EG, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992 Jul;10(7):607-13.
[1]. Bevan EG, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992 Jul;10(7):607-13.
[2]. M Aleksinskaya, et al. Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model. Bmc Pharmacology & Toxicology , 2013 , 14 (1) :1-2.